Source-grounded facts extracted from BriaCell Therapeutics Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BriaCell Therapeutics Corp. entered into Placement Agency Agreement with ThinkEquity LLC valued at $4.71 million (effective 2026-05-31).
“On May 31, 2026, BriaCell Therapeutics Corp. (the “Company”) entered into a Placement Agency Agreement (the “Agreement”) with ThinkEquity LLC”
BriaCell Therapeutics Corp. entered into Warrant Agent Agreement with Computershare Inc. and Computershare Trust Company, N.A. (effective 2026-01-15).
“On January 15, 2026, the Company also entered into a Warrant Agent Agreement (the “Warrant Agent Agreement”) with Computershare Inc. and Computershare Trust Company, N.A. (“Computershare”), pursuant to which Computershare agreed to act as transfer agent with respect to the Warrants.”
BriaCell Therapeutics Corp. entered into Placement Agency Agreement with ThinkEquity LLC valued at $30 million (effective 2026-01-13).
“On January 13, 2026, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with ThinkEquity LLC (the “Placement Agent”), pursuant to which the Company agreed to issue and sell directly to investors, in a best efforts basis the Common Units and the Pre-funded Units.”
Marc Lustig resigned as director at BriaCell Therapeutics Corp..
“On November 23, 2024, Marc Lustig resigned from the board of directors of BriaCell Therapeutics Corp. (the “Company”)”
BriaCell Therapeutics Corp. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Cash fee of 7.0% of gross proceeds; Placement Agent Warrants for 50,000 shares at $2.321 per share (effective 2024-05-14).
“In connection with the Offering, on May 14, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).”
BriaCell Therapeutics Corp. entered into Securities Purchase Agreements with certain investors valued at Gross proceeds of $5,000,000 from sale of shares and warrants (effective 2024-05-14).
“On May 14, 2024, BriaCell Therapeutics Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain investors (collectively the “Purchasers”).”
BriaCell Therapeutics Corp. shareholders approved Election of seven director nominees at the 2024-01-30 meeting.
“Proposal 2. At the Meeting, the terms of seven (7) members of the Board expired. Each of the seven (7) nominees for director (the "Nominees") were elected to serve until the next annual meeting of shareholders, or until his/her successor is duly elected or appointed, unless he/she resigns, is removed, or becomes disqualified in accordance with the Articles of Incorporation of the Company or the British Columbia Corporations Act.”
BriaCell Therapeutics Corp. shareholders approved Ratification of appointment of MNP LLP as auditors at the 2024-01-30 meeting.
“Proposal 1. At the Meeting, the shareholders ratified the appointment of MNP LLP as auditors for the Company and the authorization of the Board of Directors of the Company (the "Board") to fix the auditors' remuneration and terms of engagement.”
BriaCell Therapeutics Corp.: Amended notice of articles and articles to effect share exchange pursuant to arrangement agreement (effective 2023-08-31).
“On August 31, 2023, 2023, BriaCell Therapeutics Corp. (the “Company”) amended its articles pursuant to the previously disclosed arrangement agreement (the “Agreement”).”
BriaCell Therapeutics Corp. shareholders approved Ratification and confirmation of grant of options to officers under former stock option plan at the 2023-08-18 meeting.
“Proposal 3. At the Meeting, a majority of the votes cast by shareholders of the Company on this proposal, upon approving the SpinCo Incentive Plan, ratified, confirmed and approved a grant of an aggregate of 180,100 options to acquire shares of the Company on August 2, 2022, granted under the Company’s stock option plan, which was superseded by the Company’s omnibus equity incentive plan, to the officers listed in the table below, on August 2, 2022 (the “ Award ”).”
BriaCell Therapeutics Corp. shareholders approved Approval of the SpinCo omnibus equity incentive plan at the 2023-08-18 meeting.
“Proposal 2. At the Meeting, a majority of the votes cast by shareholders of the Company on this proposal, approved the Spinco omnibus equity incentive plan (the “SpinCo Incentive Plan”). The result of the votes to approve the SpinCo Incentive Plan was as follows: For Against Abstain Broker Non-Votes 6,179,448 705,709 4,004 1”
BriaCell Therapeutics Corp. shareholders approved Approval of the arrangement agreement and plan of arrangement with SpinCo at the 2023-08-18 meeting.
“Proposal 1. At the Meeting, not less than two-thirds of the votes cast by shareholders of the Company cast on this proposal, approved the arrangement agreement), between the Company and BriaPro Therapeutics Corp. (“SpinCo”) and the statutory plan of arrangement pursuant to Section 288 of the Business Corporations Act (British Columbia). The result of the votes to approve the arrangement agreement and the plan of arrangement was as follows: For Against Abstain Broker Non-Votes 6,814,983 71,082 3,097 0”
BriaCell Therapeutics Corp. entered into Arrangement Agreement with BriaPro Therapeutics Corp. valued at spin-out of pre-clinical pipeline assets in exchange for SpinCo common shares; SpinCo Shares represe (effective 2023-05-24).
“On May 24, 2023, BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) entered into an Arrangement Agreement (the “Arrangement Agreement”) with BriaPro Therapeutics Corp., a British Columbia corporation and wholly-owned subsidiary of the Company (“SpinCo”), pursuant to which the Company will spin out certain of its pre-clinical pipeline assets , including Bria-TILsRxTM and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (collectively, the “SpinCo Assets”), to SpinCo by way of a court-approved statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia) (the “Arrangement”).”
BriaCell Therapeutics Corp. entered into Stock Purchase Agreement with Prevail Partners, LLC valued at $4,000,000 (effective 2023-05-12).
“On May 12, 2023, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Prevail Partners, LLC, an investment fund and affiliate of InfoWorks, pursuant to which the Company agreed to issue 463,408 common shares (the “Shares”) for an aggregate purchase price of $4,000,000.”
BriaCell Therapeutics Corp. entered into Master Service and Technology Agreement with Prevail InfoWorks, Inc. valued at $5,379,945 (effective 2023-05-09).
“On May 9, 2023, BriaCell Therapeutics Corp. (the “Company”) entered into a Master Service and Technology Agreement (the “MST Agreement”) with Prevail InfoWorks, Inc. (“InfoWorks”) pursuant to which InfoWorks will provide clinical services and technologies for the Company’s upcoming pivotal study in advanced metastatic breast cancer.”
BriaCell Therapeutics Corp.: Amended Articles to raise quorum threshold for shareholder meetings to two shareholders holding at least 33 1/3% of outstanding shares (effective 2023-02-13).
“On February13, 2023, BriaCell Therapeutics Corp. (the “Company”) amended its Articles to raise the quorum threshold for shareholder meetings to two shareholders who are, or who represent by proxy, shareholders who, in the aggregate, hold at least 33 1/3% of the outstanding shares entitled to be voted at the meeting.”
BriaCell Therapeutics Corp. shareholders approved Authorize and approve an amendment to the Articles to raise the quorum threshold for shareholder meetings to two shareholders holding at least 33 1/3% of outstanding shares. at the 2023-02-09 meeting.
“Proposal 5. At the Meeting, the Company’s shareholders authorized and approved an amendment to the Articles of the Company to raise the quorum threshold for shareholder meetings to two shareholders who are, or who represent by proxy, shareholders who, in the aggregate, hold at least 33 1/3% of the outstanding shares entitled to be voted at the meeting (the “Quorum Amendment”). The result of the votes to approve the Quorum Amendment was as follows: For Against Abstain Broker Non-Votes 3,695,624 41,488 8,396 2,917,862”
BriaCell Therapeutics Corp. shareholders approved Ratify, confirm and approve a grant of 19,200 restricted share units under the Omnibus Equity Incentive Plan to the CEO on August 2, 2022. at the 2023-02-09 meeting.
“Proposal 4. At the Meeting, upon approving the Omnibus Equity Incentive Plan, the Company’s shareholders ratified, confirmed and approved a grant of 19,200 restricted share units under the Omnibus Equity Incentive Plan to the Company’s Chief Executive Officer on August 2, 2022 (the “RSU Award”). The result of the votes to approve the RSU Award was as follows: For Against Abstain Broker Non-Votes 3,622,931 96,879 25,698 2,917,862”
BriaCell Therapeutics Corp. shareholders approved Approve a new omnibus equity incentive plan. at the 2023-02-09 meeting.
“Proposal 3. At the Meeting, the Company’s shareholders approved a new omnibus equity incentive plan (the “Omnibus Equity Incentive Plan”). The result of the votes to approve the Omnibus Equity Incentive Plan was as follows: For Against Abstain Broker Non-Votes 3,169,080 548,283 28,145 2,917,862”
BriaCell Therapeutics Corp. shareholders approved Election of seven nominees as directors. at the 2023-02-09 meeting.
“Proposal 2. At the Meeting, the terms of seven (7) members of the Board expired. Each of the seven (7) nominees for director (the “Nominees”) were elected to serve until the next annual meeting of shareholders, or until his/her successor is duly elected or appointed, unless he/she resigns, is removed, or becomes disqualified in accordance with the Articles of the Company or the British Columbia Corporations Act. The result of the votes to elect the Nominees was as follows: Directors For Against Withheld Broker Non-Votes Dr. Jane Gross 3,695,837 0 49,672 2,917,861 Mr. Marc Lustig 3,651,900 0 93,608 2,917,862 Mr. Jamieson Bondarenko 3,742,891 0 2,618 2,917,861 Dr. William V. Williams 3,743,095 0 2,414 2,917,861 Dr. Rebecca Taub 3,740,940 0 4,569 2,917,861 Mr. Vaughn C. Embro-Pantalony 3,733,000 0 12,508 2,917,862 Mr. Martin Schmieg 3,739,718 0 5,791 2,917,861”
BriaCell Therapeutics Corp. shareholders approved Ratify the appointment of MNP LLP as auditors for the Company and authorize the Board to fix auditors' remuneration and terms of engagement. at the 2023-02-09 meeting.
“Proposal 1. At the Meeting, the shareholders ratified the appointment of MNP LLP as auditors for the Company and the authorization of the Board of Directors of the Company (the “Board”) to fix the auditors’ remuneration and terms of engagement. The result of the votes to ratify the appointment of MNP LLP was as follows: For Against Abstain Broker Non-Votes 6,651,809 0 11,560 1”
BriaCell Therapeutics Corp. reported Three months ended October 31, 2021 results: net income (27,533,485 ), EPS $ (1.81 ).
“: Research and development expenses $ 875,636 $ 149,062 General and administrative expenses 1,409,173 231,309 Total operating expenses 2,284,809 380,371 Operating loss (2,284,809 ) (380,371 ) Financial expenses, net (25,248,676 ) (40,956 ) Loss for the period (27,533,485 ) (421,327 ) Other comprehensive loss - Foreign currency translation adjustment - 35,340 Comprehensive loss for the period $ (27,533,485 ) $ (385,987 ) Net loss per share – basic and diluted $ (1.81 ) $ (0.54 ) Weighted average number of shares used in computing net basic and diluted”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.